Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED) - A prospective multicenter study

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Sebastian Bauer - , Philipps-Universität Marburg (Autor:in)
  • Lorenz C. Hofbauer - , Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Martina Rauner - , Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Adam Strzelczyk - , Philipps-Universität Marburg (Autor:in)
  • Christoph Kellinghaus - , Klinikum Osnabrück (Autor:in)
  • Susanne Hallmeyer-Elgner - , Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Neurologie (Autor:in)
  • Wolfgang H. Oertel - , Philipps-Universität Marburg (Autor:in)
  • Felix Rosenow - , Philipps-Universität Marburg (Autor:in)

Abstract

Purpose: To determine early changes in bone turnover markers induced by treatment with oxcarbazepine or valproate. Methods: In this prospective study, 31 adults with newly diagnosed epilepsy were included who were started on therapy with either oxcarbazepine (OXC, n=16, mean age 45.6 years, 37.5% female) or valproate (VPA, n=15, mean age 42.2 years, 33.3% female). Clinical characteristics were obtained at baseline, after 2 weeks and 3 months. In addition, blood samples were drawn at each visit. Calcium, phosphate, alkaline phosphatase (AP), receptor activator of NF-κB ligand (RANKL), osteoprotegerin (OPG), osteocalcin (OC) and cathepsin K were determined. Results: In OXC treated patients, OPG increased by 0.06. pmol/L (p= 0.0004) after 2 weeks and remained elevated by 0.05. pmol/L (p=0.02) after 3 months. Between 2 weeks and 3 months of OXC treatment, OC increased by 1.98. ng/mL (p=0.02). During the first 3 months of OXC treatment, total serum AP increased by 11%. ±. 9% (p=0.02). Compared to baseline, serum calcium raised by 0.06. mmol/L (p=0.04) after 2 weeks and by 0.07. mmol/L (p=0.004) after 3 months of OXC treatment. In VPA treated patients, a late OPG increase by 0.07. pmol/L (p=0.007) occurred after 3 months. During the first 3 months of OXC treatment, total serum AP decreased by by 7%. ±. 15% (p=0.03). No changes in OC or calcium were seen. RANKL was below detection limit in 16 out of 31 patients (52%) and did not change significantly during treatment. Cathepsin K was below detection limit at baseline in 27 out of 31 patients (87%) and was therefore not further evaluated. Phosphate did not change during treatment. Conclusion: Increased bone turnover can be measured within few weeks of newly started treatment with OXC, while significant changes under VPA treatment occurred only after 3 months. Our data suggest distinct mechanisms of increased bone turnover in different anticonvulsants. These variable mechanisms may require individual prevention and treatment strategies.

Details

OriginalspracheEnglisch
Seiten (von - bis)417-422
Seitenumfang6
FachzeitschriftEpilepsy research
Jahrgang106
Ausgabenummer3
PublikationsstatusVeröffentlicht - Okt. 2013
Peer-Review-StatusJa

Externe IDs

PubMed 23916144
ORCID /0000-0002-8691-8423/work/164196682

Schlagworte

ASJC Scopus Sachgebiete

Schlagwörter

  • Bone turnover, Osteoprotegerin, Oxcarbazepine, RANKL, Valproate